A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC

Abroad (travel likely)RecruitingPHASE3

Conditions

Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Cancer Center Hospital, Tokyo, Japan
Contact: Study coordinator (Ken Kato, M.D./Ph.D)

Study leads

Ken Kato, MD/PhD
Study Chair
National Cancer Center Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Resectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Shanghai, China · Anyang, China

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma · Unresectable Locally Advanced Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Beijing, China

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Montreal, Canada · Dublin, Ireland